Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) FCF Margin (2016 - 2026)

Amphastar Pharmaceuticals has reported FCF Margin over the past 13 years, most recently at 17.29% for Q4 2025.

  • For Q4 2025, FCF Margin rose 838.0% year-over-year to 17.29%; the TTM value through Dec 2025 reached 20.61%, down 293.0%, while the annual FY2025 figure was 20.61%, 293.0% down from the prior year.
  • FCF Margin for Q4 2025 was 17.29% at Amphastar Pharmaceuticals, down from 27.16% in the prior quarter.
  • Over five years, FCF Margin peaked at 42.63% in Q4 2021 and troughed at 5.51% in Q4 2023.
  • A 5-year average of 20.2% and a median of 24.16% in 2022 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: plummeted -4661bps in 2022 and later surged 4055bps in 2023.
  • Year by year, FCF Margin stood at 42.63% in 2021, then tumbled by -109bps to 3.98% in 2022, then crashed by -38bps to 5.51% in 2023, then surged by 262bps to 8.91% in 2024, then skyrocketed by 94bps to 17.29% in 2025.
  • Business Quant data shows FCF Margin for AMPH at 17.29% in Q4 2025, 27.16% in Q3 2025, and 23.07% in Q2 2025.